Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer.
Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer.
复制标题
循环 microRNA 作为卵巢癌诊断和预后标志物的进展
DOI：
10.7497/j.issn.2095-3941.2013.03.001
复制
发表时间：
2013-09
影响因子：
5.5
通讯作者：
Chen KX
中科院分区：
文献类型：
--
作者：
Zheng H;Liu JY;Song FJ;Chen KX
卵巢癌是妇科最致命的恶性肿瘤之一。超过70%的卵巢癌患者被诊断为晚期。晚期卵巢癌患者的5年生存率低于30%，因为缺乏有效的诊断、预后和个性化治疗的生物标志物。MicroRNA（miR）是一类主要通过转录后抑制负调控基因表达的小分子非编码RNA。卵巢癌组织中miR的研究已经开展，并显示出巨大的临床应用潜力。然而，组织样本不容易获得，因为取样会造成伤害。研究人员已经开始关注血浆/血清miR，假设血液样本可能在未来的miR研究中取代组织样本。血浆/血清miR研究仍处于早期阶段。关于其在卵巢癌早期诊断中作用的研究已取得一定进展，但血浆/血清miR谱用于卵巢癌的预后评估和个体化治疗尚不清楚。深入了解血浆/血清miR在卵巢癌中的作用将有助于卵巢癌的早期诊断和治疗。
Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.